Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Bleakley Financial Group LLC

Bleakley Financial Group LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 5.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 77,088 shares of the company’s stock after purchasing an additional 3,951 shares during the quarter. Bleakley Financial Group LLC’s holdings in Apellis Pharmaceuticals were worth $1,334,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its position in Apellis Pharmaceuticals by 108.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 70,159 shares of the company’s stock worth $1,534,000 after purchasing an additional 36,565 shares in the last quarter. Diversified Trust Co acquired a new position in shares of Apellis Pharmaceuticals in the first quarter valued at approximately $282,000. GF Fund Management CO. LTD. raised its position in shares of Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after buying an additional 573 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Apellis Pharmaceuticals by 56.4% during the first quarter. Envestnet Asset Management Inc. now owns 43,717 shares of the company’s stock valued at $956,000 after buying an additional 15,766 shares during the period. Finally, Cerity Partners LLC boosted its position in Apellis Pharmaceuticals by 16.7% during the first quarter. Cerity Partners LLC now owns 54,444 shares of the company’s stock worth $1,191,000 after acquiring an additional 7,777 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on APLS shares. Wells Fargo & Company initiated coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They set an “overweight” rating and a $32.00 price target on the stock. Raymond James Financial decreased their price target on Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 1st. Robert W. Baird upped their price objective on shares of Apellis Pharmaceuticals from $47.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. HC Wainwright reissued a “buy” rating on shares of Apellis Pharmaceuticals in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $33.47.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 31,092 shares of the company’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $23.72, for a total value of $737,502.24. Following the completion of the sale, the director owned 3,837 shares of the company’s stock, valued at $91,013.64. This represents a 89.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Cedric Francois sold 49,963 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $28.39, for a total value of $1,418,449.57. Following the completion of the sale, the chief executive officer owned 307,946 shares of the company’s stock, valued at approximately $8,742,586.94. This trade represents a 13.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 312,921 shares of company stock valued at $8,490,866 in the last quarter. Company insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:APLS opened at $28.17 on Friday. The stock has a 50-day simple moving average of $25.60 and a 200-day simple moving average of $21.45. The stock has a market capitalization of $3.56 billion, a P/E ratio of -15.48 and a beta of 0.69. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $35.72. The company has a debt-to-equity ratio of 2.90, a quick ratio of 3.16 and a current ratio of 3.77.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The firm had revenue of $171.39 million for the quarter, compared to analysts’ expectations of $187.91 million. During the same period in the previous year, the company posted ($0.30) earnings per share. Apellis Pharmaceuticals’s revenue was down 10.6% compared to the same quarter last year. Equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).